×
About 151 results

ALLMedicine™ Lung Cancer Immunotherapy Center

Research & Reviews  49 results

Overview of Lung Cancer Immunotherapy.
https://doi.org/10.1097/PPO.0000000000000488
Cancer Journal (Sudbury, Mass.); Sanmamed MF, Eguren-Santamaria I et. al.

Dec 10th, 2020 - Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the impo...

Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy.
https://doi.org/10.1158/1078-0432.CCR-20-3507
Clinical Cancer Research : an Official Journal of the Ame... Salas-Benito D, Eguren-Santamaria I et. al.

Nov 14th, 2020 - It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors...

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007372
Cancer Discovery; Li F, Huang Q et. al.

Nov 20th, 2019 - Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune respon...

Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a N...
https://doi.org/10.1002/cpt.1597
Clinical Pharmacology and Therapeutics; Yang S, Yu KH et. al.

Jul 29th, 2019 - The autoimmune adverse effects of lung cancer immunotherapy are not fully understood at the population level. Using observational data from commercial health insurance claims, we compared autoimmune diseases risk of immune checkpoint inhibitors (i...

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6695312
Journal of the National Cancer Institute; Conforti F, Pala L et. al.

May 20th, 2019 - We previously showed that therapy with anti-checkpoints T-lymphocyte-associated protein 4 (anti-CTLA-4) or antiprogrammed cell death protein 1 (anti-PD-1) agents was more effective for men as compared with women. However, because the sex-dimorphis...

see more →

Guidelines  4 results

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer
https://linkinghub.elsevier.com/retrieve/pii/S1556086418335147
Yatabe, Y.,et al

Dec 16th, 2018 - Since the 2015 WHO classification was introduced into clinical practice, the importance of immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small versus non-small cell carcinoma (NSCC), pat.

Molecular Testing for the Selection of Patients With Lung Cancer for Treatment With Targeted...
http://ascopubs.org/doi/full/10.1200/JCO.2017.76.7293
Gregory P. Kalemkerian

Mar 19th, 2018 - In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association forMolecular Pathology (AMP) recently updated their recommendations for molec.

IASLC Atlas of PD-L1 Testing in Lung Cancer
https://www.iaslc.org/publications/iaslc-atlas-pd-l1-testing-lung-cancer
IASLC

Sep 30th, 2017 - The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer is a new resource for understanding programmed cell death ligand-1 (PD-L1) immunohistochemistry (IHC) assays.

The IASLC Atlas of EGFR Testing in Lung Cancer
https://www.iaslc.org/publications/iaslc-atlas-egfr-testing-lung-cancer
Myung-Ju Ahn

Sep 30th, 2017 - The IASLC Atlas of EGFR Testing in Lung Cancer provides health care professionals with information on EGFR testing processes and facilitates clinicians’ understanding of how to interpret the results.

see more →

Clinicaltrials.gov  81 results

Overview of Lung Cancer Immunotherapy.
https://doi.org/10.1097/PPO.0000000000000488
Cancer Journal (Sudbury, Mass.); Sanmamed MF, Eguren-Santamaria I et. al.

Dec 10th, 2020 - Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the impo...

Senescent T Cells as a Resistance Mechanism to Lung Cancer Immunotherapy.
https://doi.org/10.1158/1078-0432.CCR-20-3507
Clinical Cancer Research : an Official Journal of the Ame... Salas-Benito D, Eguren-Santamaria I et. al.

Nov 14th, 2020 - It has been reported that a group of patients with advanced non-small cell lung cancer showed circulating T cells with a senescent phenotype, and an abundance of such cells is associated with worse clinical response to immune checkpoint inhibitors...

Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade
https://www.medscape.com/viewarticle/924067

Jan 22nd, 2020 - We've just come to the end of a remarkable decade of progress that has transformed how we treat—and, indeed, even how we view—lung cancer. Rewind 10 years: As we entered 2010, median survival for patients with metastatic non-small cell lung cancer...

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007372
Cancer Discovery; Li F, Huang Q et. al.

Nov 20th, 2019 - Despite substantial progress in lung cancer immunotherapy, the overall response rate in patients with KRAS-mutant lung adenocarcinoma (LUAD) remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune respon...

see more →

News  17 results

Top 5 Advances in Lung Cancer Immunotherapy Over the Past Decade
https://www.medscape.com/viewarticle/924067

Jan 22nd, 2020 - We've just come to the end of a remarkable decade of progress that has transformed how we treat—and, indeed, even how we view—lung cancer. Rewind 10 years: As we entered 2010, median survival for patients with metastatic non-small cell lung cancer...

E-sniffer predicts non-responders to lung cancer immunotherapy
https://www.reuters.com/article/us-health-lungcancer-electronic-nose/e-sniffer-predicts-non-responders-to-lung-cancer-immunotherapy-idUSKBN1W42Z2

Sep 19th, 2019 - An electronic “nose” that detects chemicals in the breath of lung cancer patients may help distinguish between those who will and will not respond to immunotherapy, a new study suggests. In the small study, the eNose was better at identifying the ...

CDF Approval for Immunotherapy Drug
https://www.staging.medscape.com/viewarticle/905500

Nov 22nd, 2018 - In two separate announcements this week, the National Institute for Health and Care Excellence (NICE) recommended pembrolizumab (Keytruda, Merck Sharpe & Dohme) as a treatment option for certain types of lung cancer, as well as for some patients w...

see more →